Healthy Living - a defensive alternative to blistering markets

Healthy Living - a defensive alternative to blistering markets

06-04-2022 | 投資觀點
Volatile markets are sinking some investors and whiplashing others. Alternatives are available for investors seeking smoother rides over the long run.
  • David Kägi
    Portfolio Manager

Speed read

  • Market gyrations increase focus on more defensive equity strategies.
  • Defensive sector company earnings less sensitive to market swings
  • Exposure to Healthy Living themes helps stabilize long-term returns

Uncertainty is the constant in today’s market. Ongoing Covid flare-ups, inflation, supply chain disruptions and now war are further intensifying an already volatile mix that’s spooking markets.

To reduce exposure to volatile market movements, investors are considering more defensive strategies. Classic defensive sectors furnish essential goods and services which consumers are unlikely to give up even in a downturn. With a steady focus on ‘healthy essentials’, RobecoSAM Sustainable Healthy Living is a thematic equity strategy that typically outperforms in down market cycles while still capturing the upside potential provided by long-term growth trends.

Amid general market misery, thematics with defensive characteristics are faring much better than other growth-focused strategies

A healthy defense

Amid general market misery, thematics with defensive characteristics are faring much better than other growth-focused strategies. As David Kägi, portfolio manager for the RobecoSAM Sustainable Healthy Living Equities strategy, explains, “Defensive sectors generally provide stable earnings that are uncorrelated with the overall stock market. They even tend to outperform when broader markets are falling.”

Figure 1 | When market volatility rises, defensive sectors generally outperform

Over the last two decades healthcare and consumer staples stocks have provided steady above-market returns, further burnishing their reputation as safer bets in times of market turmoil. Here, high market volatility has been defined as periods when annualized market absolute volatility is 10% or more.

Source: Bloomberg, Robeco

Kägi credits his strategy’s less volatile, risk-adjusted performance with its strong tilt towards healthcare and consumer staples sectors. Together these account for around two-thirds of the portfolio. “Consumer staples stocks function in a noncyclical manner, meaning they offer investors safety during recessionary climates. Food, grooming and cleaning products are typical staples that tend to generate solid profits even in slow-growth economies.” He notes consumer staples companies thrived during the pandemic’s early stages when markets overall were tanking.

Stable, risk-adjusted performance comes from a strong tilt towards healthcare and consumer staples sectors

Meanwhile, he describes his other defensive allocation, healthcare, as a perennial pursuit. “Demand for healthcare services is inelastic. People don’t ignore their health because of a dip in the business cycle. Healthcare stocks can expand earnings even in down markets.” He references healthcare costs in the US which are nearly 18% of GDP and says that globally, healthcare expenditures are rising, approaching USD 10 trillion annually.

He adds that more stable performance returns, many defensive stocks pay substantial dividends which have reliably increased through past market cycles. Their longevity is a strong signal of a high-quality stock backed by strong consumer trust, brand value, and good management. These same attributes also help staples navigate the changing challenges across economic cycles.

Pandemic effects

Early on in the pandemic as markets were falling, many segments of healthcare were resilient and displayed strong performance, from sophisticated biotech and pharmaceuticals churning out vaccines to makers of protective gear. Stocks of diagnostic and testing equipment benefited as well. Moreover, Kägi says pandemic pressures accelerated digitalization trends in healthcare, which has historically been slow to adopt new technologies. From vaccine development and clinical trials to telemedicine and health tracking apps, the pandemic catalyzed new avenues of growth across the healthcare supply chain. He is certain that new revenue channels will continue to grow even as the virus abates.

In consumer staples, he says demand for hygienic items like hand soap, disinfectants and anti-microbial wipes surged, as did over-the-counter retail medications and home remedies to relieve viral symptoms. Here too he is convinced that many Covid-induced attitudes and behavioral changes will stick post-pandemic, providing steady returns for the Strategy’s defensive stocks and clusters.


Spot on for long-term growth

Also underpinning the Strategy’s long-term growth potential are its focus on sustainability challenges that transcend market movements and mayhem over the longer term. “Society is confronting a series of serious health-related issues from rising healthcare costs and aging populations to the increasing prevalence of chronic illness.” He’s confident investments in preventative measures such as good nutrition and staying active will help reduce disease rates and curb healthcare’s cost creep.

Kägi says a focus on health across the entire human lifespan sets the portfolio apart from other healthcare theme strategies that tend to be treatment oriented. “We’re investing in companies that promote healthy living early on so that populations remain active and healthy well beyond retirement.” The Strategy’s convictions on shifts in consumer spending and preferences are so far spot on, as healthy changes in the UK’s consumer price index demonstrate. Donuts and men’s suits are out while lentils and sports bras are in.

Low risk, low gain, less pain

The cumulative performance since inception shows the Healthy Living Strategy has captured returns superior to those of global equity markets (MSCI World TR) over the long-term. What’s more, this cumulative outperformance has been achieved at lower volatility and risk relative to the benchmark – a hallmark of defensive strategies.

Figure 2 | Healthy returns over the long run

Source: Robeco1

The portfolio maintains a low beta coefficient, a key measure of its sensitivity to market fluctuations, as well as low absolute volatility, which means returns have avoided wild swings relative to broader markets (see Table 1).

Table 1 | Solid performance with low volatility indicators

Source: Robeco

Key risk performance indicators from the RobecoSAM Sustainable Healthy Living Equities (EUR) D-share, Gross of fees. Beta shown has been annualized since inception, April 2007. All other data has been annualized over 5 years ending February 2022.

Meanwhile, solid risk-adjusted performance is also demonstrated in solid upside and downside capture ratios. The Strategy’s downside capture ratio was 0.70, meaning it has reduced the portfolio’s exposure to market losses by 30%. Meanwhile, its upside capture ratio over the same time period stands at 0.78, meaning it has captured nearly 80% of the positive returns generated when markets are rising.

For conservative investors seeking solid performance without the volatility, the Strategy presents an interesting alternative. Its tilt towards noncyclical sectors helps reduce exposure to losses in down market cycles while its unique approach to rising healthcare costs allows it to benefit from long-term sociodemographic shifts already underway. For growth-oriented investors, it provides active exposure to diagnostic and digital innovation that’s opening new frontiers in health maintenance and delivery for patients and health-conscious consumers. With these features, it’s well suited for investors concerned as much with the journey as the destination.

1Gross of fees performance in EUR for the RobecoSAM Sustainable Healthy Living Equities Strategy as of 31.12.2021.
The currency in which the past performance is displayed my differ from the currency of your country of residence. Due to exchange rate fluctuations, the performance shown may increase or decrease if converted into your local currency. Periods shorter than one year are not annualized. The value of your investments may fluctuate. Past performance is no guarantee of future results. Returns gross of fees, based on gross asset value. Values and returns indicated here are before cost; neither consider the management fee as well as other administration costs related to the strategy nor the fees and costs which may be charged when subscribing, redeeming and or switching units. These have a negative effect on the returns shown. Effective October 29, 2020, select RobecoSAM equity strategies were merged onto the RCGF SICAV platform and received new inception dates, share classes, and ISIN codes. All performance prior to the RCGF SICAV merger have been calculated based on the investment policies, fees and share classes of the respective sub-strategy under the previous SICAV.


此文件之內容未經香港證監會(SFC)審核。若你對此文件的內容有任何疑問,請尋求獨立並專業的意見。此文件由 Robeco Hong Kong Limited (以下稱“荷寶”) 分發,荷寶受香港證監會監管。

此為機密文件,僅供接收者參考。任何未經荷寶事先書面同意,即複製或分發全部或部分此文件或披露其內容的行為是被禁 止的。接收此文件,即表示接受上述條款。


本文件的內容來源於我們認為可靠的資訊。 本文件向任何管轄區或國家的個 人或實體的分發及使用建立在不違背該管轄區或國家法律法規的基礎上。

投資附帶風險。歷史回報數據僅供解釋說明之用,並不構成對荷寶未來表現預期的影響。貴方的投資組合價值可能會有波 動,過往的投資業績並不保證將來的投資表現。



1. 一般事項


此網站由Robeco Hong Kong Limited(「荷寶」)擬備及刊發,荷寶是獲香港證券及期貨事務監察委員會發牌從事第1類(證券交易)、第4類(就證券提供意見)及第9類(資產管理)受規管活動的企業。荷寶不持有客戶資產,並受到發牌條件所規限。荷寶在擴展至零售業務之前,必須先得到證監會的批准。本網頁未經證券及期貨事務監察委員會或香港的任何監管當局審閱。

2. 風險披露聲明

Robeco Capital Growth Funds以其特定的投資政策或其他特徵作識別,請小心閱讀有關Robeco Capital Growth Funds的風險:

  • 部份基金可涉及投資、市場、股票投資、流動性、交易對手、證券借貸及外幣風險及小型及/或中型公司的相關風險。
  • 部份基金所涉及投資於新興市場的風險包括政治、經濟、法律、規管、市場、結算、執行交易、交易對手及貨幣風險。
  • 部份基金可透過合格境外機構投資者("QFII")及/或 人民幣合格境外機構投資者 ("RQFII")及/或 滬港通計劃直接投資於中國A股,當中涉及額外的結算、規管、營運、交易對手及流動性風險。
  • 就分派股息類別,部份基金可能從資本中作出股息分派。股息分派若直接從資本中撥付,這代表投資者獲付還或提取原有投資本金的部份金額或原有投資應佔的任何資本收益,該等分派可能導致基金的每股資產淨值即時減少。
  • 部份基金投資可能集中在單一地區/單一國家/相同行業及/或相同主題營運。 因此,基金的價值可能會較為波動。
  • 部份基金使用的任何量化技巧可能無效,可能對基金的價值構成不利影響。
  • 除了投資、市場、流動性、交易對手、證券借貸、(反向)回購協議及外幣風險,部份基金可涉及定息收入投資有關的風險包括信貨風險、利率風險、可換股債券的風險、資產抵押證券的的風險、投資於非投資級別或不獲評級證券的風險及投資於未達投資級別主權證券的風險。
  • 部份基金可大量運用金融衍生工具。荷寶環球消費新趨勢股票可為對沖目的及為有效投資組合管理而運用金融衍生工具。運用金融衍生工具可涉及較高的交易對手、流通性及估值的風險。在不利的情況下,部份基金可能會因為使用金融衍生工具而承受重大虧損(甚至損失基金資產的全部)。
  • 荷寶歐洲高收益債券可涉及投資歐元區的風險。
  • 投資者在Robeco Capital Growth Funds的投資有可能大幅虧損。投資者應該參閱Robeco Capital Growth Funds之銷售文件內的資料﹙包括潛在風險﹚,而不應只根據這文件內的資料而作出投資。

3. 當地的法律及銷售限制




4. 使用此網站



5. 投資表現



6. 第三者網站

本網站含有來自第三方的資料或第三方經營的網站連結,而其中部分該等公司與荷寶沒有任何聯繫。跟隨連結登入任何其他此網站以外的網頁或第三方網站的風險,應由跟隨該連結的人士自行承擔。荷寶並無審閱此網站所連結或提述的任何網站,概不就該等網站的內容或所提供的產品、服務或其他項目作出推許或負上任何責任。荷寶概不就使用或依賴第三方網站所載的資料而導致的任何虧損或損毀負上法侓責任,包括(但不限於)任何虧損或利益或任何其他直接或間接的損毀。 此網站以外的網頁或第三方網站皆旨在作參考之用。

7. 責任限制




8. 知識產權


9. 私隠

荷寶保證將會根據現行的資料保障法例,以保密方式處理登入此網站的人士的數據。除非荷寶需按法律責任行事,否則在未經登入此網站的人士許可,不會向第三方提供該等數據。 請於我們的私隱及Cookie政策 中查找更多詳情。 

10. 適用法律


如果您已閱讀並理解本頁並同意上述免責聲明以及同意荷寶收集和使用您的個人資料,用於私隱及Cookie政策 所列的收集和使用個人資料的目的(包括用於直接推廣荷寶的產品或服務),請點擊“我同意”按鈕。否則,請點擊“我不同意”離開本網站。